Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
These Stocks Are Moving the Most Today: Roivant Sciences, Textainer, Okta, Microsoft, Alphabet
2023-10-23 16:50
Roche agrees to buy a developer of a drug for people suffering from inflammatory bowel disease from Roivant Sciences and Pfizer in a deal worth up to $7.25 billion, Textainer is being acquired for about $2.1 billion, and Microsoft and Alphabet lead a busy earnings week.
You Might Like...
How to Get Diamond LeBron James in NBA 2K24
Save up to 70% on Xbox games for Call of Duty's 20th anniversary
How to Earn Cursed Energy in Fortnite
Apple and 4 More Quality Stocks to Buy After the Selloff
'Rate me' Subreddit issues warning to user for 'overrating' a woman's looks
Time to Buy? PC Prices Fall Amid Decreasing Demand
Google Bard AI chatbot waitlist removed, more languages added
OpenAI's head of trust and safety steps down